KR950009098B1 - Pharmaceutical composition for use in treating clot formation - Google Patents

Pharmaceutical composition for use in treating clot formation Download PDF

Info

Publication number
KR950009098B1
KR950009098B1 KR87008873A KR870008873A KR950009098B1 KR 950009098 B1 KR950009098 B1 KR 950009098B1 KR 87008873 A KR87008873 A KR 87008873A KR 870008873 A KR870008873 A KR 870008873A KR 950009098 B1 KR950009098 B1 KR 950009098B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
clot formation
treating
treating clot
mopidamol
Prior art date
Application number
KR87008873A
Other languages
English (en)
Other versions
KR880002529A (ko
Inventor
Wolfgang Eisert
Peter Gruber
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6307286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950009098(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of KR880002529A publication Critical patent/KR880002529A/ko
Application granted granted Critical
Publication of KR950009098B1 publication Critical patent/KR950009098B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
KR87008873A 1986-08-13 1987-08-13 Pharmaceutical composition for use in treating clot formation KR950009098B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3627423.2 1986-08-13
DE19863627423 DE3627423A1 (de) 1986-08-13 1986-08-13 Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung

Publications (2)

Publication Number Publication Date
KR880002529A KR880002529A (ko) 1988-05-09
KR950009098B1 true KR950009098B1 (en) 1995-08-14

Family

ID=6307286

Family Applications (1)

Application Number Title Priority Date Filing Date
KR87008873A KR950009098B1 (en) 1986-08-13 1987-08-13 Pharmaceutical composition for use in treating clot formation

Country Status (26)

Country Link
US (1) US6015577A (ko)
EP (1) EP0257344B1 (ko)
JP (1) JP2593879B2 (ko)
KR (1) KR950009098B1 (ko)
AT (1) ATE59961T1 (ko)
AU (1) AU603146B2 (ko)
BR (1) BR1100593A (ko)
CA (1) CA1302272C (ko)
CL (1) CL2004001252A1 (ko)
DD (1) DD263918A5 (ko)
DE (3) DE3627423A1 (ko)
DK (1) DK172236B1 (ko)
ES (1) ES2020974B3 (ko)
FI (1) FI873492A (ko)
GR (1) GR3001695T3 (ko)
HK (1) HK14494A (ko)
HU (1) HU202404B (ko)
IE (1) IE60862B1 (ko)
IL (1) IL83510A (ko)
NL (1) NL990001I2 (ko)
NO (2) NO175132C (ko)
NZ (1) NZ221424A (ko)
PH (1) PH27176A (ko)
PT (1) PT85525B (ko)
SG (1) SG122593G (ko)
ZA (1) ZA875947B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101413613B1 (ko) * 2006-01-27 2014-07-10 앱탈리스 파마테크, 인코포레이티드 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템
KR101489401B1 (ko) * 2006-01-27 2015-02-03 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19927689A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20040058056A1 (en) * 2001-07-06 2004-03-25 Shigemasa Osaki Drug diffusion coatings, applications and methods
MXPA04003266A (es) * 2001-10-05 2004-07-08 Combinatorx Inc Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US7485322B2 (en) * 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
EP2062580A1 (en) * 2003-04-24 2009-05-27 Boehringer Ingelheim International GmbH Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of trombin receptors
US7041286B2 (en) * 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2007537184A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血小板剤に対する耐性を治療するためのジピリダモールの使用
PT2559430E (pt) 2005-03-22 2015-10-09 Stada Arzneimittel Ag Ibuprofeno solubilizado
EP1919460A2 (en) * 2005-08-22 2008-05-14 Novartis AG Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
US20070184110A1 (en) * 2006-02-09 2007-08-09 Minutza Leibovici Dipyridamole extended-release formulations and process for preparing same
WO2007139753A2 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
ITRM20060460A1 (it) * 2006-08-31 2006-11-30 Univ Roma Uso di acido acetil salicilico in combinazione con inibitori dei canali mrp4 per il trattamento di pazienti resistenti a detto acido acetil salicilico
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
EP2203174A4 (en) * 2007-09-19 2010-09-29 Combinatorx Inc THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
NZ586332A (en) * 2007-12-17 2012-07-27 Zalicus Inc Therapeutic regimens for the treatment of immunoinflammatory disorders using dipyridamole and prednisolone
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20120276206A1 (en) 2008-03-28 2012-11-01 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
US20100080846A1 (en) * 2008-09-25 2010-04-01 Avshalom Ben-Menachem Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
WO2012162492A1 (en) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
CN103239724A (zh) * 2013-05-27 2013-08-14 成都自豪药业有限公司 抗血栓形成的联合用药物及其药物组合物
WO2018236899A1 (en) * 2017-06-19 2018-12-27 The Cleveland Clinic Foundation TREATMENT OF A DISEASE AND PROMOTION OF WEIGHT LOSS BY INHIBITING THE TMA / FMO3 / TMAO PATHWAY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2368280A1 (fr) * 1976-10-20 1978-05-19 Theramex Nouvelle composition therapeutique presentant une activite anti-agregante plaquettaire, et son procede de preparation
FR2368272A1 (fr) * 1976-10-20 1978-05-19 Theramex Compositions therapeutiques solides pour combattre l'agregation plaquettaire
LU77353A1 (ko) * 1977-05-16 1979-01-19
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
FR2513118A1 (fr) * 1981-09-18 1983-03-25 Rocador Sa Composition pharmaceutique a base de dipyridamol et de sel d'aluminium de l'acide acetylsalicylique pour combattre l'agregation plaquettaire
DE3576119D1 (de) * 1984-07-21 1990-04-05 Hoechst Ag Kombinationspraeparat aus pyrimido-pyrimidinen und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101413613B1 (ko) * 2006-01-27 2014-07-10 앱탈리스 파마테크, 인코포레이티드 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템
KR101489401B1 (ko) * 2006-01-27 2015-02-03 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템

Also Published As

Publication number Publication date
CL2004001252A1 (es) 2005-03-04
NO873370D0 (no) 1987-08-12
DE3627423A1 (de) 1988-02-18
GR3001695T3 (en) 1992-11-23
FI873492A0 (fi) 1987-08-12
HU202404B (en) 1991-03-28
DE3767408D1 (de) 1991-02-21
SG122593G (en) 1994-06-10
DE10299015I2 (de) 2005-06-16
NO1999014I1 (no) 1999-07-01
DK421187A (da) 1988-02-14
IE872152L (en) 1988-02-13
PT85525B (pt) 1990-06-29
HUT44937A (en) 1988-05-30
CA1302272C (en) 1992-06-02
US6015577A (en) 2000-01-18
IE60862B1 (en) 1994-08-24
NZ221424A (en) 1989-11-28
NL990001I1 (nl) 1999-03-01
PH27176A (en) 1993-04-02
AU603146B2 (en) 1990-11-08
ATE59961T1 (de) 1991-02-15
NO873370L (no) 1988-02-15
JPS6348219A (ja) 1988-02-29
ES2020974B3 (es) 1991-10-16
NO175132B (no) 1994-05-30
HK14494A (en) 1994-03-04
FI873492A (fi) 1988-02-14
DE10299015I1 (de) 2002-10-10
KR880002529A (ko) 1988-05-09
AU7679587A (en) 1988-02-18
BR1100593A (pt) 2002-04-02
DK421187D0 (da) 1987-08-12
PT85525A (de) 1987-09-01
ZA875947B (en) 1989-04-26
NO175132C (no) 1994-09-07
IL83510A0 (en) 1988-01-31
DK172236B1 (da) 1998-02-02
EP0257344A1 (de) 1988-03-02
IL83510A (en) 1992-02-16
JP2593879B2 (ja) 1997-03-26
EP0257344B1 (de) 1991-01-16
NL990001I2 (nl) 2000-04-03
DD263918A5 (de) 1989-01-18

Similar Documents

Publication Publication Date Title
KR950009098B1 (en) Pharmaceutical composition for use in treating clot formation
ATE63813T1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
ZA894128B (en) Use of gamma-hydroxybutryic acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism,and the compositions obtained
AR243083A1 (es) Procedimiento para la obtencion de un preparado farmaceutico.
EP0243968A3 (en) Diacetylrhein salts and their therapeutical use in the treatment of arthritis
DK481388A (da) Calciumtilskud
IL88159A0 (en) Salts of pentamidine and pharmaceutical compositions containing the same
PT86205A (en) Process for the preparation of 3-]omega-(3,5-di-t-butil-4-hydroxyphenyl)-alkanoyl"pyrroles and their de-oxy analogs useful in therapy
AU8188087A (en) Variants of hirudin, their use and their preparation
FI890477A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen 2,5-diamino-6-fluoriheksaanihapon ja sen suolojen valmistamiseksi
EP0349143A3 (en) Use of phytic acid or its salts for the prevention or treatment of hepatic diseases
EP0426573A3 (en) Phenoxypropylamine derivatives or salts thereof and antiulcer agents containing the same
ZA882096B (en) Tert.-butylamino-3-(phenyl-2'-phenoxy)-1-propanol-2-(bipranole)and its acid addition salts for use as active therapeutic substances
DE3671371D1 (de) Kombinationspraeparat.
RO105585B1 (ro) Compozitie medicamentoasa folosita in tratamentul ulcerului de gamba
CS417191A3 (en) 8-alkoxyquinolonecarboxylic acid and its salts
GR3006610T3 (ko)
CA2027593A1 (fr) Composition a activite anti-agregante plaquettaire utilisable en therapeutique
AU98941S (en) A gameboard
HU9201483D0 (en) Process for the production of 1h-rh-analogues'acid additive salts, and for the production of medical preparations containing them

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090810

Year of fee payment: 15

EXPY Expiration of term